11/29/2025
It's Science Friday at Rx4Prevention. Today's topic: mRNA flu vaccine shows promise, but…
Although a quadrivalent modified mRNA flu vaccine proved to work better than the standard inactivated flu vaccine, don’t anticipate a cutting-edge flu shot any time soon.
Here’s the backstory. Researchers compared two groups: one received the common quadrivalent flu vaccine, while the other got the mRNA counterpart. Scientists convincingly found that the mRNA vaccine gave 34.5 percent better protection against H1N1 and H3N2 influenza.
In addition to being more effective, the mRNA vaccine can be developed rapidly. The current method of choosing flu vaccine strains months ahead and producing them in eggs can cause mismatches with circulating viruses. In contrast, mRNA flu vaccines could be made in 6-8 weeks, as shown with COVID-19.
Unfortunately, the study's results coincide with the federal government's choice to end mRNA vaccine research funding.
One researcher observed that pharmaceutical companies might be worried that there's no path forward to FDA approval because it's an mRNA-based vaccine. “They're not going to invest additional millions of dollars just to be told, 'You started with the wrong material, and it's not going to be approved.'"